Navigating Antipsychotic Use in Dementia: Balancing Risks, Benefits, and Alternatives for Palliative Care Providers

Agitation is a frequent and distressing symptom in individuals with advanced dementia. It may manifest as restlessness, verbal outbursts, pacing, aggression, or resistance to care. For patients in hospice or palliative care settings, these behaviors can pose significant challenges for caregivers, impact the dignity of the patient, and strain the interdisciplinary team. Although antipsychotic medications are commonly used to manage these symptoms, their use must be approached with caution due to significant associated risks. This article explores the benefits and drawbacks of antipsychotics for dementia-related agitation and offers evidence-based alternative strategies aligned with the values of palliative care: comfort, dignity, and person-centeredness.

Understanding the Roots of Agitation in Dementia

Agitation in dementia is rarely a disease in itself; rather, it is often a symptom of unmet needs or environmental distress. Common triggers include:

• Pain or physical discomfort (constipation, infection, pressure ulcers)
• Sensory impairments (hearing or vision loss)
• Sleep disruption or fatigue
• Environmental overstimulation or unfamiliarity
• Medication side effects
• Delirium or psychiatric comorbidities

Recognizing and addressing these underlying causes is the cornerstone of non-pharmacological management. However, in some cases, pharmacologic intervention is considered when the patient's behavior becomes a threat to their own safety or the safety of others, and when non-drug interventions have failed.

Potential Benefits of Antipsychotics

In select scenarios, antipsychotics may provide short-term symptom control. Potential benefits include:

1. Reduction in Dangerous or Severe Behaviors

Antipsychotics can help reduce aggression, physical violence, or psychosis in patients with severe behavioral disturbances. In cases where patients are at risk of harming themselves or caregivers, a short course may be justified.

2. Improved Safety in Care Environments

For nursing home residents or home hospice patients exhibiting extreme agitation, antipsychotics may reduce the risk of falls, wandering, or injury by dampening impulsive or combative behavior.

3. Alleviation of Psychotic Symptoms

In some patients, antipsychotics can reduce distressing hallucinations or delusions—particularly in Lewy Body Dementiaor Parkinson’s Disease Dementia—although caution is required due to increased sensitivity to these medications.

Clinical pearl: The decision to initiate an antipsychotic should never be reflexive. It must be grounded in a careful evaluation of risks versus benefits, and only considered when non-pharmacological options have failed or are insufficient.

Significant Risks of Antipsychotic Use in Dementia

Despite their potential benefits, the harms associated with antipsychotic use in elderly patients with dementia are substantial. These include:

1. Increased Mortality

In 2005, the FDA issued a Black Box Warning for both typical and atypical antipsychotics due to a significantly increased risk of death in elderly patients with dementia-related psychosis. Most deaths were due to cardiovascular events or infections such as pneumonia.

2. Higher Stroke Risk

Antipsychotics are associated with an increased risk of cerebrovascular accidents, particularly in patients with a history of stroke or vascular dementia. This includes both ischemic and hemorrhagic strokes.

3. Worsening Cognitive Decline

Rather than stabilizing cognition, antipsychotics may accelerate cognitive decline in patients with Alzheimer’s disease and other dementias.

4. Extrapyramidal Symptoms (EPS)

Older adults are especially vulnerable to EPS including tremors, rigidity, tardive dyskinesia, and akathisia, which can reduce mobility, increase fall risk, and worsen quality of life.

5. Sedation and Increased Fall Risk

Sedation is a common side effect, often leading to falls, fractures, and increased caregiver burden. This is particularly dangerous in hospice patients who may already be frail or bed-bound.

6. Metabolic and Cardiovascular Effects

Antipsychotics—especially atypical agents like olanzapine and quetiapine—can cause hyperglycemia, weight gain, and QTc prolongation, contributing to metabolic syndrome or cardiac arrhythmias.

When (and How) to Use Antipsychotics

If non-drug interventions fail and the patient poses a risk to self or others, antipsychotics may be used with caution and for the shortest duration necessary. Clinical best practices include:

• Informed consent: Discuss risks and limited benefits with the family or healthcare proxy.
• Drug selection: Use the least sedating, lowest effective dose, and avoid agents with high EPS or anticholinergic burden.
• Regular reassessment: Evaluate efficacy and side effects within 7–14 days. Taper and discontinue if symptoms improve.

Note: Quetiapine and risperidone are commonly used in hospice, but both require monitoring. Haloperidol remains a widely used option due to familiarity, cost, and rapid onset, especially in sublingual or parenteral forms.

Non-Pharmacological Alternatives: The True First-Line Approach

Non-drug interventions are more aligned with palliative goals and are associated with fewer risks. These strategies aim to improve comfort, reduce triggers, and promote meaningful engagement.

1. Environmental Modifications

• Reduce noise, clutter, and overstimulation
• Use familiar objects, photos, and lighting
• Ensure consistency in caregivers and routines

2. Person-Centered Activities

• Music therapy, art therapy, or reminiscence therapy
• Gentle touch, aromatherapy, or massage
• Pet visits or spiritual care, depending on patient preferences

3. Behavioral Analysis and Trigger Identification

• Track when and why agitation occurs (e.g., during bathing, sundowning)
• Use this information to preemptively adjust care routines

4. Pain Management and Physical Comfort

• Use validated pain scales (e.g., PAINAD)
• Treat pain proactively in nonverbal or noncommunicative patients

5. Staff and Family Education

• Train caregivers in calm communication, de-escalation, and redirection techniques
• Reinforce that agitation is not intentional, but rather a form of communication

Other Pharmacologic Alternatives (Used Cautiously)

If non-drug approaches are exhausted and antipsychotics are contraindicated, consider:

• Citalopram: An SSRI with some evidence for mild to moderate agitation (monitor QTc)
• Prazosin: Promising in veterans with agitation or trauma-related behaviors
• Gabapentin or valproate: Limited efficacy data; sedation is common
• Cholinesterase inhibitors / memantine: Modest behavioral benefits in Alzheimer’s disease

None of these are FDA-approved for agitation in dementia, and all should be used judiciously.

Deprescribing Antipsychotics in Hospice and Palliative Care

Deprescribing is a core component of good hospice care. If a patient has been stable for 2–4 weeks or if risks outweigh benefits, tapering the antipsychotic should be considered. Signs that deprescribing is appropriate include:

• Resolution or significant improvement of agitation
• Increased sedation or falls
• Change in goals of care (e.g., nearing active dying)

Conclusion: A Values-Based Approach to Agitation Management

For palliative and hospice providers, the management of agitation in dementia is not about achieving perfect calm—it is about supporting comfort, dignity, and quality of life. Antipsychotics may offer temporary reprieve in select cases, but they should never replace a thoughtful, holistic approach to care.

As clinicians, we must lead with empathy, not sedation. The best tools at our disposal remain our ability to listen, observe, adapt, and advocate for the person behind the diagnosis.

References:

• American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 67:674–694, 2019.
• Kales H C, Gitlin L N, Lyketsos C G. Assessment and management of behavioral and psychological symptoms of dementia BMJ 2015; 350.
• Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, Other Psychotropics, and the Risk of Death in Patients With Dementia: Number Needed to Harm. JAMA Psychiatry. 2015;72(5):438–445.
• Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Therapeutic Advances in Chronic Disease. 2016;7(5):229-245.